Board of Directors
Axel Bolte, MSc., M.B.A.
President and CEO, Inozyme Pharma, Inc. and Investment Advisor, HBM Healthcare Investments AG
Thomas Dyrberg, M.D., DMSc.
Senior Partner, Novo Ventures and Novo A/S
David R. Guyer, M.D.
Executive Chairman of Ophthotech's Board of Directors
Jane Pritchett Henderson
Chief Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics
Financial Officer and Senior Vice President of Corporate Development at Voyager Therapeutics, a publicly-traded, clinical-stage gene therapy company focused on
developing life-changing treatments for severe neurological diseases. Prior to Voyager, Ms. Henderson served as Chief Financial and Business Officer of
Kolltan Pharmaceuticals, Inc., having joined the privately held biopharmaceutical company in 2013 and leading the sale of Kolltan to Celldex Pharmaceuticals, Inc.
in late 2016. Previously, Ms. Henderson served as Vice President, Business Development of ISTA Pharmaceuticals, Inc., until ISTA Pharmaceuticals was acquired
by Bausch + Lomb. Prior to ISTA Pharmaceuticals, Ms. Henderson served as Chief Financial Officer and Head of Business Development at Axerion
Pharmaceuticals, Inc., and as Chief Financial Officer and Chief Business Officer of Panacos Pharmaceuticals, Inc. In addition to her industry experience, Ms.
Henderson’s extensive healthcare investment banking experience includes the execution of more than 95 mergers and acquisitions, advisory and financing deals
as managing director and other senior roles at HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers and Salomon Brothers. Ms.
Henderson holds a B.S. in psychology from Duke University and currently serves on the board of directors of Eleven Biotherapeutics, Inc., a publicly-traded
biologics oncology company.
Former Partner, Wilmer Cutler Pickering Hale and Dorr LLP
Mike Ross, Ph.D.
Managing Partner, SV Life Sciences
Glenn P. Sblendorio, M.B.A.
President and Chief Executive Officer of Ophthotech